JoinClinicalTrials.com

• A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

  NCT04036019

  Condition:   B Cell Lymphoma
  Intervention:   Biological: CD20-directed CAR-T cells
  Sponsors:   Shanghai Tongji Hospital, Tongji University School of Medicine;   Cellular Biomedicine Group Ltd.
  Recruiting
• Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

  NCT03920631

  Condition:   B Cell Lymphomas
  Interventions:   Drug: Nivolumab;   Biological: Microtransplantation
  Sponsor:   Ahmed Galal, MD
  Recruiting
• Parsaclisib in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

  NCT03424122

  Condition:   B-cell Lymphoma
  Interventions:   Drug: Parsaclisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ibrutinib
  Sponsor:   Incyte Corporation
  Recruiting
• Study of TG-1801 in Subjects With B-Cell Lymphoma

  NCT03804996

  Condition:   B-Cell Lymphoma
  Intervention:   Drug: TG-1801
  Sponsor:   TG Therapeutics, Inc.
  Recruiting
• Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

  NCT03929107

  Condition:   B Cell Lymphoma
  Intervention:   Biological: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
  Sponsors:   Wenbin Qian;   Zhejiang Provincial Tongde Hospital
  Recruiting
• Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

  NCT03761056

  Condition:   B-cell Lymphoma
  Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Fludarabine;   Drug: Cyclophosphamide
  Sponsor:   Kite, A Gilead Company
  Recruiting
• CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

  NCT03146533

  Condition:   B Cell Lymphoma
  Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: CD19 CART
  Sponsors:   Shenzhen Second People's Hospital;   The Beijing Pregene Science and Technology Company, Ltd.
  Recruiting
• A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma

  NCT03189524

  Condition:   B-cell Lymphoma
  Intervention:   Drug: BGB-3111
  Sponsor:   BeiGene
  Recruiting
• A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

  NCT03670888

  Condition:   B Cell Lymphoma
  Interventions:   Biological: JHL1101;   Biological: Rituximab
  Sponsor:   JHL Biotech, Inc.
  Not yet recruiting
• A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

  NCT02741388

  Condition:   B-cell Lymphoma
  Interventions:   Drug: selinexor;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Oxaliplatin;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Gemcitabine
  Sponsors:   The Lymphoma Academic Research Organisation;   Karyopharm Therapeutics Inc
  Recruiting
• Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma

  NCT03824951

  Condition:   Refractory B-Cell Lymphoma
  Intervention:   Biological: Anti-CD19 iCAR NK Cells
  Sponsors:   Allife Medical Science and Technology Co., Ltd.;   Beijing Cancer Hospital
  Not yet recruiting
• Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

  NCT03824964

  Condition:   Refractory B-Cell Lymphoma
  Intervention:   Biological: Anti-CD19/CD22 CAR NK Cells
  Sponsors:   Allife Medical Science and Technology Co., Ltd.;   Beijing Cancer Hospital
  Not yet recruiting
• Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

  NCT03692767

  Condition:   Refractory B-Cell Lymphoma
  Intervention:   Biological: Anti-CD22 CAR NK Cells
  Sponsor:   Allife Medical Science and Technology Co., Ltd.
  Not yet recruiting
• Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

  NCT03690310

  Condition:   Refractory B-Cell Lymphoma
  Intervention:   Biological: Anti-CD19 CAR NK Cells
  Sponsor:   Allife Medical Science and Technology Co., Ltd.
  Not yet recruiting
• Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

  NCT02767674

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Cyclophosphamide;   Drug: Epirubicin Injectable Product;   Drug: Vindesine;   Drug: Prednisone
  Sponsor:   The First Affiliated Hospital with Nanjing Medical University
  Recruiting
• Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

  NCT03630159

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Biological: Tisagenlecleucel;   Drug: Pembrolizumab
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

  NCT02733380

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Chidamide;   Drug: Vinorelbine;   Drug: Liposomal Doxorubicin or mitoxantrone;   Drug: Dexamethasone;   Drug: Thalidomide
  Sponsor:   Henan Cancer Hospital
  Recruiting
• Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

  NCT03876028

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Biological: Tisagenlecleucel;   Drug: Ibrutinib
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

  NCT03704298

  Condition:   Refractory Large B-cell Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Axicabtagene Ciloleucel;   Biological: Utomilumab
  Sponsors:   Kite, A Gilead Company;   Pfizer
  Recruiting
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)

  NCT04002401

  Condition:   Refractory Large B-cell Lymphoma
  Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Rituximab;   Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Cyclophosphamide
  Sponsor:   Gilead Sciences
  Not yet recruiting
• CART-19 Cells for R/R B-cell Lymphoma

  NCT03391726

  Condition:   Relapsed or Refractory B-cell Lymphoma
  Intervention:   Other: CART-19 cells
  Sponsor:   Fujian Medical University
  Recruiting
• CNS Prophylaxis in Diffuse Large B-cell Lymphoma

  NCT02777736

  Condition:   Diffuse Large B-cell Lymphoma
  Intervention:   Drug: Methotrexate
  Sponsor:   Czech Lymphoma Study Group
  Recruiting
• Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

  NCT04056975

  Condition:   Relapsed or Refractory B-cell Lymphoma
  Intervention:   Biological: Recombinant Anti-CD19m-CD3 Antibody Injection
  Sponsors:   Generon (Shanghai) Corporation Ltd.;   Beijing Cancer Hospital
  Not yet recruiting
• Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

  NCT03513601

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: (R)-CHOP regimen;   Drug: (R)-CVP regimen
  Sponsor:   Mingzhi Zhang
  Recruiting
• Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

  NCT03797170

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Other: Gut microbiota samples
  Sponsor:   University of Bologna
  Recruiting
• CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT04026100

  Condition:   Diffuse Large B-cell Lymphoma
  Intervention:   Biological: CTA101
  Sponsors:   The First Affiliated Hospital with Nanjing Medical University;   Nanjing Bioheng Biotech Co., Ltd.
  Not yet recruiting
• Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

  NCT03719560

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Methotrexate;   Drug: Cytarabine
  Sponsor:   Brown University
  Not yet recruiting
• Mature B-Cell Lymphoma And Leukemia Study III

  NCT01046825

  Condition:   Mature B-Cell Lymphoma
  Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
  Sponsor:   St. Jude Children's Research Hospital
  Recruiting
• Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

  NCT03208556

  Condition:   Relapsed or Refractory B-cell Lymphoma
  Interventions:   Biological: iPD1 CD19 eCAR T cells;   Drug: Fludarabine and cyclophosphamide
  Sponsors:   Peking University;   Marino Biotechnology Co., Ltd.
  Recruiting
• Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

  NCT03576443

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Idelalisib
  Sponsor:   Nordic Lymphoma Group
  Recruiting
• A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

  NCT03579082

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Decitabine
  Sponsor:   Mingzhi Zhang
  Recruiting
• A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

  NCT03650933

  Condition:   Diffuse Large B-Cell Lymphoma, Unspecified Site
  Interventions:   Biological: G-CHOP;   Biological: R-CHOP
  Sponsor:   Nanjing Yoko Biomedical Co., Ltd.
  Not yet recruiting
• Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

  NCT03681535

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Radiation: Radiation Therapy
  Sponsor:   Duke University
  Recruiting
• Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

  NCT03415399

  Condition:   Lymphoma, B-Cell
  Intervention:   Biological: ET190L1 ARTEMIS™ T cells
  Sponsors:   Eureka Therapeutics Inc.;   Peking University
  Recruiting
• Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

  NCT03104478

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Procedure: Biological samples collection
  Sponsor:   The Lymphoma Academic Research Organisation
  Recruiting
• A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT03873025

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Combination Product: Pembrolizumab and CXD101
  Sponsors:   University College, London;   Celleron Therapeutics Ltd.;   Merck Sharp & Dohme Corp.
  Not yet recruiting
• A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT02763319

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)
  Sponsors:   MorphoSys AG;   ICON Clinical Research
  Recruiting
• Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

  NCT03399513

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Ibrutinib Oral Capsule [Imbruvica];   Drug: R-CHOEP chemotherapy
  Sponsors:   University Hospital Muenster;   Janssen-Cilag G.m.b.H
  Recruiting
• A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

  NCT03688152

  Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: INCB053914;   Drug: INCB050465
  Sponsor:   Incyte Corporation
  Recruiting
• Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03777085

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: TQB2303;   Drug: Rituximab
  Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  Recruiting
• Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

  NCT03036904

  Conditions:   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma
  Interventions:   Drug: Venetoclax;   Drug: Rituximab;   Drug: Etoposide;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Doxorubicin Hydrochloride
  Sponsors:   Weill Medical College of Cornell University;   Genentech, Inc.;   Massachusetts General Hospital;   M.D. Anderson Cancer Center
  Recruiting
• 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma

  NCT03121456

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Other: 18F-FDG PET SCAN;   Other: MRI DIFFUSION
  Sponsor:   Centre Antoine Lacassagne
  Recruiting
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT03670901

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Biological: JHL1101;   Biological: MabThera
  Sponsor:   JHL Biotech, Inc.
  Not yet recruiting
• A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy

  NCT03677154

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Mosunetuzumab;   Drug: Tocilizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

  NCT04002622

  Condition:   Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
  Intervention:   Drug: TQB2450
  Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  Not yet recruiting
• A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Vincristine Placebo;   Drug: Prednisone;   Drug: Polatuzumab vedotin Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

  NCT02449265

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Radiation: Consolidation involved-site radiotherapy (ISRT);   Radiation: Consolidation involved-field radiotherapy (IFRT);   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
  Sponsor:   Wuhan University
  Recruiting
• The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

  NCT02449278

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Radiation: Consolidation involved-site radiotherapy (ISRT);   Radiation: Consolidation involved-field radiotherapy (IFRT);   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
  Sponsor:   Wuhan University
  Recruiting
• Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation

  NCT02692248

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Dexamethasone
  Sponsors:   Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea;   Janssen-Cilag, S.A.
  Recruiting
• Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT03589469

  Conditions:   Diffuse Large B-Cell Lymphoma Refractory;   Diffuse Large B-cell Lymphoma Recurrent
  Intervention:   Drug: Loncastuximab tesirine
  Sponsor:   ADC Therapeutics S.A.
  Recruiting
• Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03936153

  Condition:   Diffuse Large B-cell Lymphoma (DLBCL)
  Intervention:   Drug: abexinostat
  Sponsor:   Xynomic Pharmaceuticals, Inc.
  Not yet recruiting
• Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

  NCT01599559

  Condition:   Primary Mediastinal B-cell Lymphoma
  Interventions:   Other: observation;   Radiation: 3D-Conformal Radiotherapy (3D-CRT)
  Sponsor:   International Extranodal Lymphoma Study Group (IELSG)
  Recruiting
• KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

  NCT02471911

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: KPT-330;   Drug: Rituximab;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Dexamethasone
  Sponsors:   Weill Medical College of Cornell University;   Karyopharm Therapeutics Inc
  Recruiting
• Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma

  NCT02753062

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: bendamustine, rituximab
  Sponsors:   Asan Medical Center;   Cheolwon Suh
  Recruiting
• A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT03992339

  Condition:   Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  Intervention:   Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
  Sponsor:   Antengene Corporation
  Not yet recruiting
• A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT02957019

  Condition:   Diffuse Large B-cell Lymphoma (DLBCL)
  Interventions:   Drug: L19-IL2 - Ph I;   Drug: L19-IL2 at RD - Ph II;   Drug: Rituximab
  Sponsor:   Philogen S.p.A.
  Recruiting
• Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

  NCT02898259

  Conditions:   B Cell Lymphoma;   Lymphoma
  Interventions:   Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Rituximab
  Sponsors:   Brian Hill, MD, PhD;   The Cleveland Clinic
  Recruiting
• Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT02405078

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Chemotherapy;   Procedure: Computed Tomography;   Drug: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466

  Condition:   Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.;   Drug: Cyclophosphamide;   Drug: Fludarabine
  Sponsor:   Kite, A Gilead Company
  Recruiting
• Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

  NCT03994913

  Conditions:   Refractory B-Cell Non-Hodgkin Lymphoma;   Relapsed B-cell Non-Hodgkin Lymphoma
  Intervention:   Biological: CAR-CD19 T Cells
  Sponsors:   Carsgen Therapeutics, Ltd.;   First Affiliated Hospital of Zhejiang University;   RenJi Hospital
  Not yet recruiting
• Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma

  NCT03880279

  Condition:   Lymphoma, B-Cell
  Intervention:   Biological: TAC01-CD19
  Sponsor:   Triumvira Immunologics, Inc.
  Not yet recruiting
• Indolent Non Follicular Lymphomas Prognostic Project

  NCT02904577

  Condition:   Indolent B-Cell Lymphomas
  Intervention:   Other: Any treatment, watch and wait policy included
  Sponsor:   Fondazione Italiana Linfomi ONLUS
  Recruiting
• Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy

  NCT03569696

  Condition:   Lymphoma, B-Cell
  Intervention:   Biological: nivolumab
  Sponsor:   Meirav Kedmi MD
  Recruiting
• Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

  NCT02992834

  Condition:   Lymphoma, B Cell
  Interventions:   Biological: IL-2 pre-treated CD19 cells;   Biological: IL-7/IL-15 pre-treated CD19 cells
  Sponsor:   jiangjingting
  Not yet recruiting
• Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

  NCT02474550

  Conditions:   Diffuse Large B Cell Lymphoma;   Neutropenia, Febrile
  Intervention:  
  Sponsor:   Ajou University School of Medicine
  Recruiting
• A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma

  NCT03307746

  Condition:   B Cell Lymphoma
  Intervention:   Drug: Varlilumab
  Sponsors:   University Hospital Southampton NHS Foundation Trust;   University Hospital Plymouth NHS Trust;   The Christie NHS Foundation Trust;   Oxford University Hospitals NHS Trust;   Celldex Therapeutics;   Cancer Research UK
  Recruiting
• Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma

  NCT03458546

  Condition:   Lymphoma, B-Cell
  Intervention:   Drug: Roflumilast
  Sponsor:   The University of Texas Health Science Center at San Antonio
  Recruiting
• Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

  NCT02891590

  Conditions:   Chronic Lymphocytic Leukemia;   B-cell Lymphomas
  Intervention:   Drug: DTRMWXHS-12
  Sponsor:   Zhejiang DTRM Biopharma
  Recruiting
• A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT02600897

  Condition:   Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Rituximab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

  NCT02542111

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Bortezomib;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin
  Sponsor:   Ruijin Hospital
  Recruiting
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

  NCT03837873

  Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Transformed Lymphoma
  Interventions:   Drug: Rituximab;   Drug: Etoposide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Cisplatin;   Drug: Cytarabine
  Sponsor:   Institute of Hematology & Blood Diseases Hospital
  Recruiting
• Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

  NCT03892525

  Conditions:   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Selicrelumab;   Drug: Atezolizumab
  Sponsors:   The Lymphoma Academic Research Organisation;   Roche Pharma AG
  Recruiting
• Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

  NCT03939182

  Conditions:   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
  Interventions:   Drug: Abexinostat;   Drug: Ibrutinib
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Janssen Scientific Affairs, LLC;   Xynomic Pharmaceuticals, Inc.
  Recruiting
• An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)

  NCT02354846

  Condition:   B-cell Lymphoma
  Intervention:  
  Sponsor:   Yonsei University
  Recruiting
• Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

  NCT02660710

  Conditions:   Diffuse Large B-cell Lymphoma;   HIV
  Intervention:   Drug: R-CHOP
  Sponsors:   UNC Lineberger Comprehensive Cancer Center;   John E. Fogarty International Center (FIC);   National Institutes of Health (NIH);   National Cancer Institute (NCI)
  Recruiting
• CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

  NCT03854994

  Conditions:   B Cell Lymphoma;   B-cell Acute Lymphoblastic Leukemia
  Intervention:   Biological: Anti-CD19 CAR-T Cells Injection
  Sponsors:   Yan'an Affiliated Hospital of Kunming Medical University;   KAEDI
  Recruiting
• Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas

  NCT03985696

  Condition:   Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
  Intervention:   Other: blood sample
  Sponsor:   University Hospital, Limoges
  Recruiting
• Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

  NCT03206671

  Condition:   Mature B-cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Rituximab window;   Drug: Additional doses of Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin hydrochloride;   Drug: Vindesine Sulfate;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Vincristine
  Sponsors:   University Hospital Muenster;   Deutsche Krebshilfe e.V., Bonn (Germany)
  Recruiting
• Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

  NCT02900716

  Conditions:   Chronic Lymphocytic Leukemia;   B-Cell Lymphoma
  Interventions:   Drug: DTRMWXHS-12;   Drug: DTRM-505;   Drug: DTRM-555
  Sponsor:   Zhejiang DTRM Biopharma
  Recruiting
• A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL

  NCT03060850

  Condition:   B-cell Lymphoma
  Intervention:   Drug: AC0010MA
  Sponsor:   Hangzhou ACEA Pharmaceutical Research Co., Ltd.
  Recruiting
• Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

  NCT03281551

  Conditions:   B-cell Acute Lymphoblastic Leukemia;   B-cell Lymphoma
  Intervention:   Drug: PZ01 CAR-T cells
  Sponsors:   Pinze Lifetechnology Co. Ltd.;   Chinese Academy of Sciences;   Navy General Hospital, Beijing
  Recruiting
• Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT02570542

  Conditions:   Diffuse Large B-cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-cell Lymphoma (DLBCL);   Refractory Diffuse Large B-cell Lymphoma (DLBCL)
  Interventions:   Procedure: leukapheresis;   Drug: Plerixafor;   Drug: carmustine, etoposide, cytarabine, melphalan;   Procedure: Autologous Stem Cell Transplantation
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Columbia University;   NorthShore University HealthSystem;   University of Rochester;   Medical College of Wisconsin;   University of Nebraska;   Sanofi;   University Hospitals Seidman Cancer Center
  Recruiting
• Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

  NCT03129828

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Ibrutinib and Bortezomib + R-CHOP
  Sponsors:   Prof. Dr. Clemens Schmitt;   Charite University, Berlin, Germany;   Janssen-Cilag Ltd.
  Recruiting
• CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

  NCT03881761

  Conditions:   B-Cell Lymphoma Stage I;   Refractory;   Relapsed
  Intervention:   Biological: CD19/CD20 bispecific CAR-T cells
  Sponsors:   Henan Cancer Hospital;   Henan Hualong Biotechnology Company
  Recruiting
• CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

  NCT03287817

  Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   DLBCL
  Intervention:   Biological: AUTO3
  Sponsor:   Autolus Limited
  Recruiting
• In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

  NCT01976585

  Condition:   Low-Grade B-cell Lymphoma
  Interventions:   Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
  Sponsors:   Joshua Brody;   Celldex Therapeutics
  Recruiting
• Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

  NCT03346642

  Condition:   Primary Mediastinal Large B-cell Lymphoma
  Interventions:   Drug: Decitabine;   Drug: GVD chemotherapy;   Drug: SHR-1210
  Sponsor:   Chinese PLA General Hospital
  Recruiting
• CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

  NCT03029338

  Conditions:   Lymphomas Non-Hodgkin's B-Cell;   Relapse
  Intervention:   Biological: CD19 CAR T cells
  Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Union Stem cell & gene engineering Co.LTD
  Recruiting
• Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

  NCT03259529

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Bendamustine hydrochloride;   Drug: Gemcitabine 500 mg;   Drug: Gemcitabine 700 mg;   Drug: Gemcitabine 1000 mg;   Drug: Nivolumab;   Drug: Rituximab
  Sponsor:   St. Petersburg State Pavlov Medical University
  Recruiting
• Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

  NCT03656835

  Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma
  Intervention:   Procedure: Molecular Nanotechnology
  Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT03072771

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Blinatumomab;   Procedure: Autologous stem cell transplant;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral blood draws
  Sponsors:   Washington University School of Medicine;   Amgen
  Recruiting
• A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT02734771

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Brentuximab vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone
  Sponsors:   Patrick Reagan;   Seattle Genetics, Inc.
  Recruiting
• Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

  NCT03305445

  Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
  Sponsors:   Icahn School of Medicine at Mount Sinai;   Bristol-Myers Squibb
  Recruiting
• Treatment for Advanced B-Cell Lymphoma

  NCT01859819

  Conditions:   Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
  Interventions:   Drug: Rituximab;   Drug: IT Cytarabine
  Sponsor:   New York Medical College
  Recruiting
• Lenalidomide Based Immunotherapy in the Treatment of DLBCL

  NCT03715296

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Lenalidomide 25mg
  Sponsor:   Ruijin Hospital
  Recruiting
• Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

  NCT03949062

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
  Sponsor:   Ruijin Hospital
  Recruiting
• A Trial of Radiotherapy and Durvalumab in DLBCL

  NCT03610061

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Durvalumab;   Radiation: Radiotherapy
  Sponsors:   Austin Health;   Olivia Newton-John Cancer Research Institute;   AstraZeneca
  Recruiting
• A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  NCT03136497

  Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: ABT-199;   Drug: Ibrutinib;   Drug: Rituximab
  Sponsors:   Hackensack Meridian Health;   Janssen Scientific Affairs, LLC;   Genentech, Inc.
  Recruiting
• Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

  NCT03311958

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Nivolumab, IV, 240 mg
  Sponsor:   Fox Chase Cancer Center
  Recruiting
• Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

  NCT03639181

  Condition:   B-cell Non-Hodgkin's Lymphoma
  Intervention:   Biological: GB226
  Sponsor:   Genor Biopharma Co., Ltd.
  Recruiting
• Chidamide With R-CHOP Regimen for DLBCL Patients

  NCT03201471

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Chidamide + R-CHOP regimen
  Sponsor:   First Affiliated Hospital of Zhejiang University
  Recruiting
• Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

  NCT03263026

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Enzastaurin Hydrochloride;   Other: R-CHOP + placebo
  Sponsor:   Denovo Biopharma LLC
  Recruiting
• Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

  NCT03105596

  Condition:   B-cell Non-Hodgkin's Lymphoma
  Intervention:   Drug: Chidamide plus DICE Regimen
  Sponsor:   Peking University
  Not yet recruiting
• A Study of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

  NCT02857998

  Condition:   Mature B-cell Neoplasms
  Intervention:   Drug: HMPL-523
  Sponsor:   Hutchison Medipharma Limited
  Recruiting
• Chidamide Plus R-CHOP in Elderly DLBCL

  NCT02753647

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Chidamide
  Sponsor:   Ruijin Hospital
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

  NCT03671018

  Condition:   B-cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab vedotin;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Tocilizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Reduced Chemotherapy in Low Risk DLBCL

  NCT02752815

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   Ruijin Hospital
  Recruiting
• A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

  NCT03677141

  Condition:   B-cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab Vedotin;   Drug: Rituxumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Tocilizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Bortezomib Maintenance in High Risk DLBCL

  NCT01965977

  Condition:   Diffuse Large B Cell Lymphoma
  Intervention:   Drug: Bortezomib
  Sponsors:   Samsung Medical Center;   Janssen, LP
  Recruiting
• Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT03719989

  Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
  Intervention:   Drug: azacitidine plus R-GDP
  Sponsor:   Seoul National University Hospital
  Not yet recruiting
• Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

  NCT03484819

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
  Interventions:   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

  NCT03367143

  Condition:   Diffuse Large B-Cell Lymphoma Refractory
  Interventions:   Drug: Lenalidomide;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide
  Sponsor:   Ruijin Hospital
  Recruiting
• Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

  NCT02658968

  Conditions:   Relapsed, Diffuse Large B-cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Intervention:   Drug: Betalutin
  Sponsor:   Nordic Nanovector
  Recruiting
• QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma

  NCT04052061

  Conditions:   Diffuse Large B Cell Lymphoma;   Large-cell Lymphoma;   Lymphoma, B-Cell;   Lymphoma
  Intervention:   Biological: CD19 t-haNK
  Sponsor:   NantKwest, Inc.
  Not yet recruiting
• RICE-ibrutinib in Relapsed DLBCL

  NCT02955628

  Conditions:   Diffuse Large B Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Recurrent
  Intervention:   Drug: Ibrutinib-RICE
  Sponsors:   Singapore General Hospital;   Janssen, LP
  Recruiting
• A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

  NCT03571568

  Condition:   Indolent B-Cell Non-Hodgkin Lymphoma
  Intervention:   Biological: BI1206
  Sponsor:   BioInvent International AB
  Recruiting
• Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

  NCT03850028

  Condition:   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  Intervention:   Other: 89Zr-atezolizumab PET scans
  Sponsors:   University Medical Center Groningen;   VU University Medical Center;   Stichting Hemato-Oncologie voor Volwassenen Nederland;   Hoffmann-La Roche
  Recruiting
• First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL

  NCT02388581

  Condition:   Gastric Diffuse Large B-cell Lymphoma
  Intervention:   Drug: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
  Sponsors:   National Health Research Institutes, Taiwan;   National Taiwan University Hospital;   Mackay Memorial Hospital;   China Medical University Hospital;   Taichung Veterans General Hospital;   Changhua Christian Hospital;   National Cheng-Kung University Hospital;   Chang Gung Memorial Hospital;   Kaohsiung Medical University
  Recruiting
• Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT

  NCT03298412

  Condition:   High-risk Diffuse Large B-cell Lymphoma
  Intervention:   Drug: Blinatumomab
  Sponsor:   Amgen
  Recruiting
• Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

  NCT03401853

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Rituximab
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Rituximab Hyaluronidase and Combination Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

  NCT03864419

  Conditions:   Burkitt Lymphoma;   KSHV-associated Multicentric Castleman Disease;   Diffuse Large B-Cell Lymphoma
  Interventions:   Biological: Rituximab or Rituximab Hyaluronidase Human;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Drug: Etoposide
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Not yet recruiting
• A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

  NCT04049825

  Condition:   Relapsed or Refractory Diffuse Large B-cell Lymphoma
  Intervention:   Drug: OPB-111077
  Sponsor:   Otsuka Pharmaceutical Co., Ltd.
  Recruiting
• Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

  NCT03985189

  Condition:   Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
  Intervention:   Drug: ME-401
  Sponsor:   Kyowa Kirin Co., Ltd.
  Recruiting
• PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

  NCT03488251

  Conditions:   Non-hodgkin Lymphoma,B Cell;   Refractory Diffuse Large B-Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma
  Intervention:   Drug: MT-3724
  Sponsor:   Molecular Templates, Inc.
  Recruiting
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

  NCT03571828

  Conditions:   Diffuse Large B-cell Lymphoma(DLBCL);   Mantle Cell Lymphoma (MCL);   Follicular Lymphoma (FL)
  Intervention:   Drug: AMG 562
  Sponsor:   Amgen
  Recruiting
• Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)

  NCT03340766

  Condition:   Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
  Interventions:   Drug: Blinatumomab;   Drug: Pembrolizumab
  Sponsors:   Amgen;   Merck Sharp & Dohme Corp.
  Recruiting
• OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

  NCT01478542

  Condition:   CD20+ Aggressive B-Cell Lymphoma
  Interventions:   Drug: Conventional Vincristine;   Drug: Liposomal Vincristine;   Drug: Ricover-scheme rituximab;   Drug: optimised rituximab-schedule
  Sponsors:   University Hospital, Saarland;   German High-Grade Non-Hodgkin's Lymphoma Study Group;   Spectrum Pharmaceuticals, Inc
  Recruiting
• Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL

  NCT02564744

  Conditions:   Diffuse Large B-Cell Lymphoma;   B-cell Non-Hodgkin's Lymphoma
  Interventions:   Drug: Debio 1562;   Drug: Rituximab
  Sponsor:   Debiopharm International SA
  Recruiting
• ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

  NCT04049513

  Conditions:   Lymphomas Non-Hodgkin's B-Cell;   Diffuse Large B-cell Lymphoma (DLBCL);   Primary Mediastinal B-cell Lymphoma (PMBCL);   Transformed Follicular Lymphoma (TFL);   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL)
  Interventions:   Biological: WZTL002-1 (1928T2z CAR-T cells);   Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
  Sponsors:   Malaghan Institute of Medical Research;   Wellington Zhaotai Therapies Limited
  Not yet recruiting
• PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

  NCT03645395

  Conditions:   Non-hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma
  Intervention:   Drug: MT-3724
  Sponsor:   Molecular Templates, Inc.
  Recruiting
• Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

  NCT03990961

  Conditions:   Diffuse Large B Cell Lymphoma;   Lymphoma
  Intervention:   Drug: Pembrolizumab
  Sponsors:   University of Chicago;   Merck Sharp & Dohme Corp.
  Not yet recruiting
• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  NCT04002947

  Conditions:   Diffuse Large B-Cell Lymphoma;   Non Hodgkin's Lymphoma;   DLBCL;   NHL
  Interventions:   Drug: DA-EPOCH;   Biological: Rituximab;   Drug: CHOP;   Drug: Acalabrutinib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas

  NCT03467373

  Conditions:   B-Cell Lymphoma;   Non-Hodgkin Lymphoma
  Interventions:   Drug: RO7082859;   Drug: Obinutuzumab (G);   Drug: Rituximab (R);   Drug: Tocilizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

  NCT02836925

  Conditions:   Indolent B-cell Lymphoma;   Hepatitis C
  Interventions:   Drug: Ledipasvir+Sofosbuvir;   Drug: Sofosbuvir+Velpatasvir
  Sponsor:   Fondazione Italiana Linfomi ONLUS
  Recruiting
• Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

  NCT03244176

  Condition:   Lymphomas Non-Hodgkin's B-Cell
  Intervention:   Drug: Avelumab
  Sponsors:   Austin Health;   Merck KGaA, Darmstadt, Germany
  Recruiting
• Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

  NCT03664297

  Condition:   Mature B Cell Neoplasms
  Intervention:   Drug: SHR1459
  Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
  Recruiting
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  NCT03223610

  Conditions:   Lymphoma;   Non-Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma;   Burkitt Lymphoma
  Interventions:   Drug: Venetoclax;   Drug: Ibrutinib;   Drug: Prednisone;   Drug: Obinutuzumab;   Drug: Revlimid (lenalidomide)
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

  NCT03422523

  Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Atezolizumab;   Drug: Rituximab;   Drug: Gemcitabine 1000 mg;   Drug: Oxaliplatin 100 MG
  Sponsors:   University Hospital Southampton NHS Foundation Trust;   Hoffmann-La Roche
  Recruiting
• Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

  NCT03742258

  Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Biological: Rituximab;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659;   Drug: Vincristine Sulfate
  Sponsors:   Northwestern University;   National Cancer Institute (NCI)
  Recruiting
• A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

  NCT03483688

  Condition:   B-cell Non-Hodgkin Lymphoma
  Intervention:   Biological: CD19-directed CAR-T cells
  Sponsors:   Peking Union Medical College Hospital;   Cellular Biomedicine Group Ltd.
  Not yet recruiting
• Marginal Zone Lymphoma Cohort in Korea

  NCT02732236

  Condition:   Lymphoma, B-Cell, Marginal Zone
  Intervention:   Other: Rituximab
  Sponsor:   Dong-A University Hospital
  Recruiting
• Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

  NCT03372837

  Condition:   Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL
  Intervention:   Drug: Rituximab
  Sponsor:   SymBio Pharmaceuticals
  Recruiting
• FT516 in Subjects With Advanced Hematologic Malignancies

  NCT04023071

  Conditions:   Acute Myelogenous Leukemia;   B-cell Lymphoma
  Interventions:   Drug: FT516;   Drug: Rituximab;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: IL-2
  Sponsor:   Fate Therapeutics
  Not yet recruiting
• Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

  NCT03684694

  Conditions:   Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma
  Intervention:   Drug: Loncastuximab Tesirine and Ibrutinib
  Sponsor:   ADC Therapeutics S.A.
  Recruiting
• Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

  NCT03939026

  Conditions:   Relapsed/Refractory Large B Cell Lymphoma;   Relapsed/Refractory Follicular Lymphoma
  Interventions:   Genetic: ALLO-501;   Biological: ALLO-647;   Drug: Fludarabine;   Drug: Cyclophosphamide
  Sponsor:   Allogene Therapeutics
  Recruiting
• Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

  NCT01959698

  Conditions:   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Stage I Diffuse Large B-Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Carboplatin;   Drug: Carfilzomib;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Rituximab
  Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Amgen
  Recruiting
• DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

  NCT02633111

  Conditions:   B-cell Non-Hodgkin Lymphoma;   Aggressive
  Interventions:   Other: collected at pre-treatment tumor biopsy;   Other: Peripheral blood tests;   Device: PET/CT
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Mayo Clinic;   M.D. Anderson Cancer Center;   University of Pennsylvania;   University of Miami
  Recruiting
• A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

  NCT02955823

  Condition:   Diffuse Large B-cells Non-Hodgkin Lymphoma
  Intervention:   Drug: Rituximab-Dexamethasone-Lenalidomide
  Sponsor:   Fondazione Italiana Linfomi ONLUS
  Recruiting
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  NCT04045028

  Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   B-Cell Lymphoma
  Interventions:   Drug: Tiragolumab;   Drug: Daratumumab;   Drug: Rituximab
  Sponsor:   Genentech, Inc.
  Recruiting
• Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

  NCT03255018

  Conditions:   Non-Hodgkin Lymphoma;   Lymphoma;   Diffuse Large B-Cell Lymphoma;   Gray Zone Lymphoma;   Primary Central Nervious System Lymphoma
  Intervention:   Biological: Pembrolizumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

  NCT03207178

  Condition:   Recurrent or Refractory B Cell Malignancy
  Intervention:   Biological: Mixed CD19/CD20 CAR-T Transfer
  Sponsors:   Shanghai Longyao Biotechnology Inc., Ltd.;   Xuzhou Medical University;   Shanghai Jiao Tong University School of Medicine
  Recruiting
• Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

  NCT04058470

  Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Follicular Lymphoma Grade IIIb;   Transformed Lymphoma;   EBV-Positive DLBCL, Nos;   ALK-Positive Anaplastic Large Cell Lymphoma
  Interventions:   Drug: Toripalimab;   Drug: R-CHOP Protocol
  Sponsor:   Huiqiang Huang
  Not yet recruiting
• Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma

  NCT03321643

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Richter Syndrome;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Atezolizumab;   Drug: Gemcitabine;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Biological: Rituximab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Biomarker Guided Treatment in DLBCL

  NCT04025593

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: chidamide;   Drug: decitabine
  Sponsor:   Ruijin Hospital
  Recruiting
• R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

  NCT02628405

  Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
  Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
  Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
  Recruiting
• Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

  NCT03736616

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Etoposide;   Biological: Rituximab;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Melphalan;   Other: Autologous HSCT;   Drug: Acalabrutinib
  Sponsors:   Swedish Medical Center;   Acerta Pharma BV
  Not yet recruiting
• Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients

  NCT03318835

  Condition:   Thalidomide
  Interventions:   Drug: Thalidomide combined with R-CHOP;   Drug: R-CHOP
  Sponsor:   Fudan University
  Recruiting
• R-DA-EDOCH Versus R-CEOP90, w/o Upfront Auto-HSCT in Young Patients With Intermediate/High-risk DLBCL

  NCT03213977

  Condition:   Diffuse Large B-cell Lymphoma
  Interventions:   Drug: R-DA-EPOCH;   Drug: R-DA-EPOCH + auto-HSCT;   Drug: R-CEOP90;   Drug: R-CEOP90 + auto-HSCT
  Sponsor:   Fujian Medical University
  Recruiting
• Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

  NCT02900651

  Condition:   Diffuse Large B-cell Lymphoma
  Intervention:   Drug: MAK683
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

  NCT02772822

  Condition:   Diffuse Large B Cell Lymphoma
  Interventions:   Drug: SCT400 plus CHOP;   Drug: Rituximab plus CHOP
  Sponsor:   Sinocelltech Ltd.
  Not yet recruiting
• Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

  NCT02431988

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Procedure: Leukapheresis;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CAR19 T-Cells
  Sponsor:   University College, London
  Recruiting
• GEN3013 (DuoBody®-CD3xCD20) Safety Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

  NCT03625037

  Conditions:   Diffuse Large B-cell Lymphoma;   High-grade B-cell Lymphoma;   Primary Mediastinal Large B-cell Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
  Intervention:   Biological: GEN3013 (DuoBody®-CD3xCD20)
  Sponsor:   Genmab
  Recruiting
• The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma

  NCT03576807

  Condition:   Relapsed or Refractory B-cell Lymphomas
  Intervention:   Drug: CD20 CAR-T cells
  Sponsor:   Xin Wang
  Recruiting
• Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03373019

  Conditions:   Chidamide;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Neoplasm by Histology;   Neoplasms;   Lymphoproliferative Disorders;   Lymphatic Diseases;   Immunoproliferative Disorders;   Immune System Diseases;   Lymphoma, Non-Hodgkin;   Cyclophosphamide;   Rituximab;   Gemcitabine;   Cisplatin;   Dexamethasone;   HDAC Inhibitor
  Intervention:   Drug: Chidamide combined with R-GDP
  Sponsor:   Fudan University
  Recruiting
• MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

  NCT03932955

  Condition:   Lymphoma
  Intervention:   Biological: MC-19PD1 CAR-T cells
  Sponsor:   Peking University
  Recruiting
• Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

  NCT03696784

  Conditions:   Lymphoma;   Lymphoma, B-Cell;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases
  Interventions:   Biological: iC9-CAR19 T cells;   Drug: Bendamustine;   Drug: Fludarabine;   Drug: AP1903
  Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Bellicum Pharmaceuticals;   V Foundation
  Recruiting
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

  NCT02541565

  Conditions:   Composite Lymphoma;   Grade 3b Follicular Lymphoma;   Stage I Diffuse Large B-Cell Lymphoma;   Stage I Follicular Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage II Follicular Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage III Follicular Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma;   Stage IV Follicular Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

  NCT03161054

  Condition:   Aggressive Non-Hodgkin Lymphoma
  Interventions:   Drug: Prednisone;   Drug: Vinorelbine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Rituximab
  Sponsor:   Fondazione Italiana Linfomi ONLUS
  Recruiting
• Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

  NCT03440567

  Conditions:   CCND1 Positive;   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Avelumab;   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab;   Biological: Utomilumab
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

  NCT03505762

  Condition:   B-Cell Non-Hodgkin Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

  NCT03118180

  Condition:   Lymphoma
  Intervention:   Biological: CD19 targeted chimeric antigen receptor T cells
  Sponsors:   Zhejiang University;   Innovative Cellular Therapeutics Co., Ltd.
  Recruiting
• Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

  NCT03038672

  Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  Interventions:   Biological: Nivolumab;   Drug: Varlilumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

  NCT03793140

  Conditions:   Lymphoma;   Leukemia
  Intervention:   Drug: CPI-613
  Sponsors:   Memorial Sloan Kettering Cancer Center;   City of Hope Medical Center;   Massachusetts General Hospital;   M.D. Anderson Cancer Center;   George Washington University
  Recruiting
• BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

  NCT02933320

  Conditions:   B-cell Lymphoma;   Chronic Lymphocytic Leukaemia;   Waldenström Macroglobulinaemia
  Interventions:   Biological: BI-1206 single agent dose escalation phase;   Biological: BI-1206 single agent expansion phase;   Biological: Combination of BI-1206 with Rituximab
  Sponsor:   Cancer Research UK
  Recruiting
• Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

  NCT04023916

  Conditions:   Diffuse Large B-Cell Lymphoma;   Sintilimab;   TP53 Mutation
  Intervention:   Drug: Sintilimab-R-CHOP
  Sponsor:   Chinese Academy of Medical Sciences
  Not yet recruiting
• Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma

  NCT02494700

  Condition:   Lymphoma
  Intervention:   Radiation: Radiation Therapy
  Sponsor:   M.D. Anderson Cancer Center
  Recruiting
• Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma

  NCT03150329

  Conditions:   Grade 3a Follicular Lymphoma;   Grade 3b Follicular Lymphoma;   Recurrent Classical Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Classical Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Vorinostat
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

  NCT03332121

  Condition:   CD20 Positive B Cell Non-Hodgkin's Lymphoma
  Intervention:   Biological: B001
  Sponsor:   Shanghai Pharmaceuticals Holding Co., Ltd
  Recruiting
• Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

  NCT03189836

  Condition:   Lymphoma
  Interventions:   Biological: ACTR707;   Biological: rituximab
  Sponsor:   Unum Therapeutics Inc.
  Recruiting
• A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

  NCT03758989

  Condition:   DLBCL
  Interventions:   Drug: Rituximab Prednisone;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   University of Rochester
  Recruiting
• CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

  NCT03579927

  Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
  Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Not yet recruiting
• Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

  NCT02213913

  Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
  Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
  Sponsors:   University of Chicago;   National Cancer Institute (NCI)
  Recruiting
• Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

  NCT02436707

  Condition:   Lymphoma
  Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: G-CSF
  Sponsors:   Canadian Cancer Trials Group;   Janssen, LP;   Roche Pharma AG
  Recruiting
• A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

  NCT03757000

  Conditions:   B-cell Lymphoma Recurrent;   B-cell Chronic Lymphocytic Leukemia
  Intervention:   Drug: YY-20394
  Sponsor:   Shanghai YingLi Pharmaceutical Co. Ltd.
  Recruiting
• High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma

  NCT02531841

  Condition:   Diffuse Large B-cell-lymphoma
  Interventions:   Drug: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);   Drug: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
  Sponsors:   University Hospital Freiburg;   German Federal Ministry of Education and Research;   International Extranodal Lymphoma Study Group (IELSG)
  Recruiting
• R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

  NCT02842931

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: R-DA-EPOCH-21;   Drug: R-DA-EPOCH-21 + auto-SCT;   Drug: R-mNHL-BFM-90;   Drug: R-mNHL-BFM-90 + auto-SCT
  Sponsors:   National Research Center for Hematology, Russia;   National Research Center for Hematology
  Recruiting
• Rituximab, Bendamustine and Melphalan Chemo-immunotherapy Followed by Reinfusion of One's Own Stem Cell for Treatment of B-cell Lymphoma in Elderly Patients

  NCT03352765

  Condition:   Lymphoma
  Interventions:   Drug: rituximab;   Drug: bendamustine;   Drug: melphalan;   Procedure: Autologous Stem Cell Transplantation (ASCT)
  Sponsor:   Memorial Sloan Kettering Cancer Center
  Recruiting
• Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

  NCT03356054

  Condition:   DLBCL
  Interventions:   Combination Product: R-DHAP;   Drug: Brentuximab Vedotin
  Sponsor:   Stichting Hemato-Oncologie voor Volwassenen Nederland
  Not yet recruiting
• Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

  NCT04007029

  Conditions:   CD19 Positive;   CD20 Positive;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma
  Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Tocilizumab
  Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   Parker Institute for Cancer Immunotherapy
  Not yet recruiting
• Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

  NCT03478514

  Conditions:   Mantle Cell Lymphoma;   B Cell Lymphoma
  Interventions:   Drug: Palbociclib;   Drug: Ibrutinib
  Sponsors:   Alliance Foundation Trials, LLC.;   Pfizer
  Recruiting
• Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

  NCT03900377

  Condition:   Lymphoma, B-cell, Diffuse
  Intervention:   Drug: SyB L-0501RI
  Sponsor:   SymBio Pharmaceuticals
  Not yet recruiting
• Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression

  NCT03977623

  Condition:   Lymphoma, Large B-Cell, Diffuse
  Intervention:  
  Sponsor:   Samsung Medical Center
  Not yet recruiting
• Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

  NCT03964090

  Conditions:   Central Nervous System Lymphoma;   Secondary Central Nervous System Lymphoma
  Interventions:   Drug: TEDD-R;   Drug: TEDDI-R;   Drug: Ibrutinib;   Drug: Cytarabine;   Drug: Isavuconazole
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

  NCT03720457

  Conditions:   CD19-positive;   Diffuse Large B-cell Lymphoma;   Follicular Lymphoma
  Intervention:   Drug: Human CD19 targeted T Cells Injection
  Sponsors:   Hrain Biotechnology Co., Ltd.;   Shanghai Zhongshan Hospital
  Recruiting
• Split-Dose R-CHOP for Older Adults With DLBCL

  NCT03943901

  Conditions:   Diffuse Large B Cell Lymphoma;   DLBCL;   Cancer
  Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Biological: Pegfilgrastim
  Sponsors:   University of Wisconsin, Madison;   Medical College of Wisconsin
  Not yet recruiting
• A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

  NCT03299738

  Condition:   Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  Intervention:   Biological: C-CAR011
  Sponsors:   Cellular Biomedicine Group Ltd.;   Tianjin Medical University Cancer Institute and Hospital
  Not yet recruiting
• Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

  NCT03540303

  Condition:   Relapsed Non Hodgkin Lymphoma
  Intervention:   Drug: CAR19 T cells carrying cytoplasmic activated PD-1
  Sponsors:   Henan Cancer Hospital;   The Pregene (ShenZhen) Biotechnology Company, Ltd.
  Recruiting
• A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

  NCT03571308

  Condition:   Non Hodgkin Lymphoma
  Intervention:   Drug: R-CHOP + acalabrutinib
  Sponsor:   University Hospital Southampton NHS Foundation Trust
  Recruiting
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

  NCT01434472

  Conditions:   Post-Transplant Lymphoproliferative Disorder;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Radiation: Indium In-111 Ibritumomab Tiuxetan;   Drug: Mycophenolate Mofetil;   Other: Pharmacological Study;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan;   Drug: Fludarabine
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients

  NCT01357733

  Condition:   Lymphoma, Large B-Cell, Diffuse
  Intervention:   Other: Early interim FDG PET/CT after 1 cycle of R-CHOP
  Sponsor:   The Catholic University of Korea
  Recruiting